ensitrelvir
Sign in to savethumb|right|75px|Xocova in a Japanese blister pack
Key facts
- Drug.image
- Ensitrelvir.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Xocova
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AE11
- Drug.legal_status
- JP: Rx-only
- Drug.elimination_half life
- 42–48 hours
- Drug.CAS_number
- 2647530-73-0
- Drug.CAS_number2
- 2757470-18-9
- Drug.PubChem
- 162533924
- Drug.DrugBank
- DB18834
- Drug.ChemSpiderID
- 115007411
- Drug.UNII
- PX665RAA3H
- Drug.KEGG
- D12353
- Drug.synonyms
- S-217622
- Drug.IUPAC_name
- 1-(2,4,5-Trifluorobenzyl)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-(6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-1,3,5-triazinane-2,4-dione
- Drug.C
- 22
via Wikipedia infobox
Article
7 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- Names
- Research
- References
thumb|right|75px|Xocova in a Japanese blister pack
Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19. It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor. It is taken by mouth.